Danaher Co. (NYSE:DHR) Shares Sold by First Citizens Financial Corp

First Citizens Financial Corp trimmed its position in shares of Danaher Co. (NYSE:DHR) by 2.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,587 shares of the conglomerate’s stock after selling 37 shares during the period. First Citizens Financial Corp’s holdings in Danaher were worth $441,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Duncan Williams Asset Management LLC raised its position in shares of Danaher by 103.8% in the 3rd quarter. Duncan Williams Asset Management LLC now owns 4,176 shares of the conglomerate’s stock valued at $1,161,000 after purchasing an additional 2,127 shares in the last quarter. Abacus Wealth Partners LLC raised its stake in Danaher by 4.3% during the third quarter. Abacus Wealth Partners LLC now owns 2,795 shares of the conglomerate’s stock valued at $777,000 after buying an additional 114 shares in the last quarter. Czech National Bank lifted its holdings in Danaher by 4.2% during the 3rd quarter. Czech National Bank now owns 130,939 shares of the conglomerate’s stock worth $36,404,000 after buying an additional 5,320 shares during the last quarter. AMF Tjanstepension AB bought a new position in Danaher during the third quarter worth $5,923,000. Finally, Trust Co of the South acquired a new position in Danaher in the third quarter worth $372,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of DHR opened at $270.68 on Friday. The company has a 50-day moving average of $271.15 and a two-hundred day moving average of $258.43. The stock has a market cap of $200.49 billion, a price-to-earnings ratio of 45.88, a PEG ratio of 4.55 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a one year low of $182.09 and a one year high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the business posted $2.05 EPS. The company’s revenue was down 2.9% on a year-over-year basis. On average, equities research analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.40%. Danaher’s dividend payout ratio is presently 18.31%.

Insiders Place Their Bets

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Linda Filler sold 3,928 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the transaction, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 in the last quarter. 11.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DHR. The Goldman Sachs Group raised their target price on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Stifel Nicolaus increased their target price on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Barclays boosted their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a report on Wednesday, July 24th. Leerink Partners boosted their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Danaher in a report on Friday, September 6th. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $282.12.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.